CA-FORESCOUT
24.1.2024 07:02:27 CET | Business Wire | Press release
In the last year, the world’s critical infrastructure – the medical, power, communications, waste, manufacturing, and transportation equipment that connects people and machines – has been under near-constant attack. Forescout Research – Vedere Labs recorded more than 420 million attacks between January and December 2023. That is 13 attacks per second, a 30% increase from 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240123671589/en/
2023 Global Threat Roundup Highlights from Forescout Research (Graphic: Business Wire)
Forescout, a global cybersecurity leader, unveiled the global findings of recorded attacks in its Adversary Engagement Environment (AEE) in the new report, “2023 Global Threat Roundup.” The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure.
Despite the formidable challenges posed by the ongoing surge in cyber-activity, there is an optimistic path forward. Elisa Costante, VP of Research at Forescout Research – Vedere Labs, highlights the potential for positive change, stating, "While it's true that current efforts have fallen short in fully harnessing crucial technology to fortify critical assets and assess risks, there is an opportunity for improvement."
Read the blog: 2023 Global Threat Roundup: Trends in Cyberattacks, Exploits and Malware
Here are the top five insights from Forescout Research:
-
Not Yet Dormant: Log4j Dampens Software Library Exploits
Exploits against software libraries are witnessing a decline due to the waning popularity of Log4j exploits. This lull has given rise to a surge in exploits targeting network infrastructure and Internet of Things (IoT) devices.
Among the IoT landscape, the spotlight falls on IP cameras, building automation systems, and network-attached storage, emerging as the most sought-after targets for malicious actors.
Only 35% of exploited vulnerabilities made an appearance in the Cybersecurity and Infrastructure Security Agency's (CISA) Known Exploited Vulnerabilities (KEV) list. This divergence emphasizes the need for a proactive and comprehensive approach to cybersecurity, transcending reliance on known vulnerability databases.
-
OT Protocols Bear the Brunt
Operational Technology (OT) finds itself under relentless assault, with five key protocols bearing the brunt of persistent attacks. The primary targets include protocols used in industrial automation and power sectors, such as Modbus, subject to a staggering one-third of all attacks, closely followed by Ethernet/IP, Step7, and DNP3, each accounting for approximately 18% of the onslaught. IEC10X rounds out this list with 10% of attacks, leaving the remaining 2% distributed among various protocols, with BACnet emerging as the majority.
Building automation protocols, such as BACnet, experience less frequent scans. However, the relative scarcity of scans belies an alarming trend—targeted exploits against vulnerabilities in building automation devices are more prevalent.
-
Post-Exploitation Tactics Shift
Persistence tactics mark a 50% surge from 3% in 2022, along with discovery (roughly 25%) and execution (the other roughly 25%). While most observed commands used by threat actors remain targeted at generic Linux systems, a notable trend involves specific commands executed for network operating systems found on widely used routers.
-
Malware Families Remain Strong
Malware families persist as formidable threats. The Agent Tesla Remote Access Trojan (RAT) commands a significant 16% share of observed malicious activity. Following closely are variants of the Mirai botnet, comprising 15%, and the Redline info stealer, holding its ground at 10%.
Among command-and-control servers, Cobalt Strike emerges as the undisputed leader, commanding a substantial 46% share, trailed by Metasploit at 16%, and the emerging Sliver C2 at 13%. Most of these servers are in the United States, constituting 40% of the global landscape, with China and Russia following at 10% and 8%, respectively.
-
Threats Unleashed Across 163 Countries
Threat actors have cast a digital net far and wide, impacting 163 countries. The United States stands as the primary target, bearing the brunt with 168 malicious actors setting their sights on the nation. Other countries include the United Kingdom (88), Germany (77), India (72), and Japan (66).
The usual suspects boast high concentrations of threat actors: China (155), Russia (88), and Iran (45), collectively representing nearly half of all identified threat groups. The crosshairs of these malicious entities are predominantly fixed on three key sectors: Government, Financial Services, and Media and Entertainment. As the primary pillars of societal infrastructure, these industries are at the forefront of cyber warfare, emphasizing the need for heightened security measures and collaborative efforts.
Costante continues, “The key lies in achieving comprehensive visibility, ensuring real-time contextual awareness of every device, whether managed or unmanaged. By doing so, large enterprises can transition from a reactive defense posture to a more proactive approach, steering clear of the futile game of security whack-a-mole. This shift towards enhanced visibility and proactive defense strategies signals a brighter outlook for critical infrastructure.”
For more information, download the full report, “2023 Global Threat Roundup,” now at https://www.forescout.com/resources/research-report_2023-threat-roundup.
How Forescout Research Works
Forescout Research employs its Adversary Engagement Environment (AEE) to conduct analysis, leveraging a blend of real and simulated connected devices. This dynamic environment functions as a robust tool, enabling the pinpointing of incidents and the identification of intricate threat actor patterns at a granular level. The overarching objective is to elevate responses to complex critical infrastructure attacks by leveraging the detailed insights and understanding derived from this specialized deception environment. The AEE is maintained by Vedere Labs, a leading global team dedicated to uncovering vulnerabilities in and threats to critical infrastructure. Forescout products directly leverage this research, which is also shared openly with vendors, agencies, and other researchers.
About Forescout
Forescout Technologies, Inc., a global cybersecurity leader, continuously identifies, protects and helps ensure the compliance of all managed and unmanaged connected cyber assets – IT, IoT, IoMT and OT. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide vendor-agnostic, automated cybersecurity at scale. The Forescout® Platform delivers comprehensive capabilities for network security, risk and exposure management, and extended detection and response. With seamless context sharing and workflow orchestration via ecosystem partners, it enables customers to more effectively manage cyber risk and mitigate threats.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123671589/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
